Smoking and dietary factors associated with moderate-to-severe acne in French adolescents and young adults: results of a survey using a representative sample P Wolkenstein, L Misery, JM Amici, R Maghia, S Branchoux, C Cazeau, ... Dermatology 230 (1), 34-39, 2015 | 88 | 2015 |
Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study) A Abergel, M Rotily, S Branchoux, R Akremi, L de Léotoing, A Vainchtock, ... Clinics and research in hepatology and gastroenterology 40 (3), 340-348, 2016 | 25 | 2016 |
Atopic dermatitis burden scale: creation of a specific burden questionnaire for families C Méni, C Bodemer, A Toulon, S Merhand, N Perez‐Cullell, S Branchoux, ... Journal of the European Academy of Dermatology and Venereology 27 (11), 1426 …, 2013 | 20 | 2013 |
Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: a systematic literature review S Branchoux, C Bellera, A Italiano, D Rustand, AF Gaudin, V Rondeau Critical Reviews in Oncology/Hematology 137, 35-42, 2019 | 19 | 2019 |
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from … S Branchoux, CL Sofeu, AF Gaudin, M Kurt, A Moshyk, A Italiano, ... ESMO open 7 (1), 100340, 2022 | 16 | 2022 |
P0747: Health related quality of life and utility values in chronic hepatitis C patients: A cross-sectional study in France, the Uk and Germany S Pol, J Chevalier, S Branchoux, R Perry, G Milligan, AF Gaudin Journal of Hepatology, S606, 2015 | 16 | 2015 |
Difficulty associated with donning medical compression stockings: results from a survey comparing two different compression stockings JP Benigni, S Branchoux, I Bacle, C Taieb Women’s Health 9 (3), 291-300, 2013 | 8 | 2013 |
A review of overall survival extrapolations of immune-checkpoint inhibitors used in health technology assessments by the French health authorities V Grumberg, S Roze, J Chevalier, J Borrill, AF Gaudin, S Branchoux International journal of technology assessment in health care 38 (1), e28, 2022 | 7 | 2022 |
The burden of osteoarthritis: development and validation of a new assessment tool (BONe’S) F Rannou, P Bertin, L Grange, S Branchoux, JN Dachicourt, C Taieb Current medical research and opinion 30 (4), 741-751, 2014 | 6 | 2014 |
A Comparison of alternative network meta-analysis methods in the presence of nonproportional hazards: a case study in first-line advanced or metastatic renal cell carcinoma S Cope, K Chan, H Campbell, J Chen, J Borrill, JR May, W Malcolm, ... Value in Health 26 (4), 465-476, 2023 | 4 | 2023 |
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma S Petersohn, B McGregor, SL Klijn, JR May, F Ejzykowicz, M Kurt, M Dyer, ... Journal of Comparative Effectiveness Research 12 (8), e230004, 2023 | 1 | 2023 |
1753P Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France MS Negrier, FP Colrat, J Bonastre, C Chamielec, S Teitsson, C Knight, ... Annals of Oncology 33, S1339-S1340, 2022 | 1 | 2022 |
PCN21 efficacy and safety in previously untreated, advanced/metastatic renal cell carcinoma–a systematic literature review update CW Kraan, L Nientker, J May, B Malcolm, F Ejzykowicz, M Kurt, DS Chun, ... Value in Health 23, S424, 2020 | 1 | 2020 |
PCN42 Real-World Effectiveness in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma–a Systematic Literature Review Update AM Trip, J May, B Malcolm, F Ejzykowicz, M Kurt, DS Chun, S Ho, ... Value in Health 23, S428, 2020 | 1 | 2020 |
PCN214 cost-effectiveness analysis of nivolumab in combination with ipilimumab versus sunitinib for the first-line treatment of intermediate-to poor-risk advanced renal cell … S Branchoux, S Négrier, C de Peretti, B Malcolm, J May, L Marie, ... Value in Health 22, S477, 2019 | 1 | 2019 |
Disparités régionales des hospitalisations pour complication de l’hépatite chronique C en 2012 M Rotily, A Abergel, S Branchoux, R Akremi, L de Léotoing, A Vainchtock, ... Santé publique 29 (2), 215-227, 2017 | 1 | 2017 |
Mean annual Cost of patients hospitalized for chronic hepatitis C In France: the hepc-lone study A Abergel, M Rotily, AF Gaudin, LL De, A Vainchtock, R Akremi, ... Value in Health 17 (7), A364, 2014 | 1 | 2014 |
Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study L Albigès, C Bellera, S Branchoux, M Arnaud, A Gouverneur, S Néré, ... Clinical Genitourinary Cancer 22 (2), 295-304. e6, 2024 | | 2024 |
MSR137 Consideration of Competing Risks in Early Setting in Oncology and Impact on the Survival Estimates: To Explicitly Model Them? An Example of a French Real-World Cohort in … L Chillotti, F Colrat, P Diez-Andreu, A Brouquet, AF Gaudin, F Bugnard, ... Value in Health 26 (12), S419, 2023 | | 2023 |
HSD117 Healthcare Resources Utilization (HCRU) and Exploration of the Patient Journey through Claims Database: An Application on Advanced Renal Cell Carcinoma (ARCC) Patients … I Durand-Zaleski, L Albigès, S Branchoux, H Lemasson, A Gouverneur, ... Value in Health 26 (12), S316, 2023 | | 2023 |